MESO Mesoblast Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: MESO

Price (delayed)

$7.5

Market cap

$761.1M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.91

Enterprise value

$805.54M

mesoblast; (asx: msb; nasdaq:meso) is a world leader in innovative cell-based medicines. we have leveraged our proprietary technology platforms based on specialized cells known as mesenchymal lineage adult stem cells ...

Highlights
The quick ratio has soared by 95% YoY
The EPS has increased by 25% YoY
The debt is up by 9% year-on-year
The company's revenue fell by 5% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.mesoblast.com/
Peers: NWBO

Key stats

What are the main financial stats of MESO
Market
Shares outstanding
101.48M
Market cap
$761.1M
Enterprise value
$805.54M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.2
Price to sales (P/S)
84.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
111.06
Earnings
Revenue
$7.25M
EBIT
-$53.49M
EBITDA
N/A
Free cash flow
-$59.33M
Per share
EPS
-$0.91
Free cash flow per share
-$0.73
Book value per share
$6.25
Revenue per share
$0.09
TBVPS
$1.15
Balance sheet
Total assets
$670.29M
Total liabilities
$161.55M
Debt
$122M
Equity
$508.73M
Working capital
$53.79M
Liquidity
Debt to equity
0.24
Current ratio
2.71
Quick ratio
2.6
Net debt/EBITDA
N/A
Margins
EBITDA margin
N/A
Gross margin
100%
Net margin
-1,007.3%
Operating margin
-811.7%
Efficiency
Return on assets
-10.9%
Return on equity
-14.5%
Return on invested capital
-57.3%
Return on capital employed
-8.4%
Return on sales
-737.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MESO stock price

How has the Mesoblast stock price performed over time
Intraday
2.88%
1 week
20.19%
1 month
18.67%
1 year
13.64%
YTD
240.91%
QTD
49.7%

Financial performance

How have Mesoblast's revenue and profit performed over time
Revenue
$7.25M
Gross profit
$7.25M
Operating income
-$58.88M
Net income
-$73.06M
Gross margin
100%
Net margin
-1,007.3%
MESO's operating income is up by 22% year-on-year
The operating margin rose by 18% year-on-year
Mesoblast's net income has increased by 13% YoY
The net margin is up by 8% year-on-year

Growth

What is Mesoblast's growth rate over time

Valuation

What is Mesoblast stock price valuation
P/E
N/A
P/B
1.2
P/S
84.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
111.06
The EPS has increased by 25% YoY
The stock's P/B is 46% above its last 4 quarters average of 0.8 but 16% below its 5-year quarterly average of 1.4
The stock's price to sales (P/S) is 48% more than its last 4 quarters average of 55.3 and 32% more than its 5-year quarterly average of 62.1
The company's revenue fell by 5% YoY

Efficiency

How efficient is Mesoblast business performance
MESO's ROIC is up by 30% YoY
The ROS has increased by 14% YoY
The ROA has grown by 13% YoY
MESO's ROE is up by 12% year-on-year

Dividends

What is MESO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MESO.

Financial health

How did Mesoblast financials performed over time
The quick ratio has soared by 95% YoY
MESO's current ratio has surged by 90% year-on-year
The debt is 76% smaller than the equity
The debt is up by 9% year-on-year
Mesoblast's debt to equity has increased by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.